Overview

Full Product Details

Author:   Lawton Robert Burns
Publisher:   Springer International Publishing AG
Imprint:   Palgrave Macmillan
Edition:   1st ed. 2022
Weight:   1.166kg
ISBN:  

9783031107382

ISBN 10:   3031107381
Pages:   655
Publication Date:   20 October 2022
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Chapter 1        Introduction to the value chaina)      What is a value chain b)      How does a value chain work c)      Value chains versus supply chains d)      Issues with the term “value” e)      Balancing cost, quality, and access to innovative products   Chapter 2        Introduction to the intermediaries in the healthcare value chain a)      Number and range of intermediaries b)      MCOs, PBMs, GPOs, wholesalers c)      Nagging questions about value added by intermediaries d)      Continuing calls and efforts to “dis-intermediate” the intermediaries   Chapter 3        Overview of GPOs a)      What are GPOs b)      Types of GPOs in healthcare c)      Goals of GPOs d)      Confusing GPOs and IDNs (integrated delivery networks)   Chapter 4        History of GPOs (co-authored with David Cassak) a)      Early history of groups: 1910-1950s b)      Rise of local shared service organizations: 1960s-1970s c)      Emergence of contract compliance d)      Emergence of product portfolios e)      Rise of national and regional groups: 1970s-1980s f)       Desperately seeking compliance: 1980s-1990s g)      Dealing with healthcare reform, capitation, and managed care: 1990s h)      Competitive threat posed by IDNs: 1990s i)        Competitive threat posed by Columbia/HCA j)        Group mergers: 1990s k)      Aftermath: Consolidated vendors, consolidated buyers l)        Value and performance challenges in the new millennium m)   Senate hearings overview n)      Group mergers in the new millennium o)      Growing threat of regional GPOs   Chapter 5        Performance of GPOs a)      GPO operations and strategy b)      Hospital prices c)      Value of group purchasing d)      GPO fees e)      GPO contracting practices f)       GPO customer service and satisfaction g)      GPO clinical review processes h)      GPO oversight, codes of conduct, and self-regulation i)        GPO competition: national and regional   Chapter 6        Analysis of Specific GPO Issues a)      Price transparency b)      Exclusionary agreements c)      New market entry and access to innovative technology d)      Differentiation versus commodification of GPOs e)      Drug shortages   Chapter 7        Overview of PBMs a)      What are PBMs b)      Goals of PBMs c)      Range of PBM functions & services to employers/insurers d)      Types of PBMs in healthcare e)      PBM business models f)       Types of formularies and fees g)      Relationship between MCOs and PBMs h)      Direct versus indirect contracting for PBM services by employers i)        Growth of PBMs tied to rise of outpatient care and IPAs     Chapter 8        History of PBMs a)      Early PBMs (PCS, Medco) and claims administration: 1960s-1970s b)      Early PBMs (DPS, Pharmacy Gold) as pharmacy departments in staff model HMOs c)      Online claims processing and efficient benefits administration: 1980s d)      Role of HMOs and PBMs as countervailing power to Big Pharma: 1980s e)      Rise of mail-order pharmacies: 1980s f)       Shift to include cost and clinical controls in 1990s (e.g., tiers) g)      Vertical pharma-PBM mergers in early 1990s h)      Regulatory and government scrutiny of PBM mergers i)        New PBM functions in formulary design, DUR, & disease management j)        Growth of PBM covered lives & growth in pharmaceutical benefits by employers k)      Vertical mergers of PBMs with retail pharmacies (Rite Aid-PCS; CVS-Caremark): 1990s and 2000s l)        Horizontal consolidation of PBMs (ESI-Medco) in the new millennium m)   Government scrutiny of PBMs as possible source of high drug costs n)      PBMs and pay-for-performance models   Chapter 9        Performance of PBMs a)      Issues in measuring PBM performance b)      Market share trends: script volumes and covered lives c)      Prescription drug management indicators d)      Impact of GPO rebates on Medicare Part D premiums e)      Rise in formulary exclusions f)       Trends in out-of-pocket drug spending g)      Trends in employers’ receipt of PBM rebates h)      Trends in percentage change in list and net drug prices i)        Trends and sources of rising PBM profits   Chapter 10      Analysis of Specific PBM Issues a)      Uneasy relationship between PBMs and Big Pharma b)      Rising drug prices c)      Lack of transparency d)      Insourcing versus outsourcing the PBM function e)      Competition for PBM contracts f)       Role of PBMs in opioid epidemic  

Reviews

“Throughout the book, Burns does a nice job ... summaries which still apply today. ... this is an impressive text that will guide readers through the evolution of these two critically important but often under-recognized industries.” (Kevin A. Schulman, Health Affairs, healthaffairs.org, December 1, 2023)

Author Information

Lawton Robert Burns is the James Joo-Jin Kim Professor at the Wharton School of the University of Pennsylvania, USA and Professor in the Departments of (a) Health Care Management and (b) Management. He is also past Director of the Wharton Center for Health Management & Economics, and since 2013, Co-Director of the Life Sciences and Management Program (LSMP) at the University of Pennsylvania. From 2007–2014, he served as Chair of the Health Care Management Department.  

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions